Skip to main content
OpenTrials
Completed

NCT Number: NCT07431866

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF.

The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

24 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Fortrea Clinical Research Unit Inc ( Site 0001)

Daytona Beach, Florida, 32117, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has a body mass index (BMI) ≥18 and ≤32 kg/m^2

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

  • Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
  • Has a history of cancer (malignancy)

Treatment and study plan

Rosuvastatin

Drug

Oral administration

Furosemide

Drug

Oral administration

MK-2828

Drug

Oral administration

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the AUC0-inf of rosuvastatin.

  2. Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Furosemide

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the AUC0-inf of furosemide.

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    Time frame: Up to approximately 1 month

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    Time frame: Up to approximately 2 weeks

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in who discontinue study treatment due to an AE will be reported.

  3. Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Rosuvastatin

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the AUC0-last of rosuvastatin.

  4. Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Furosemide

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the AUC0-last of furosemide.

  5. Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Rosuvastatin

    Time frame: At designated time points (up to approximately 24 hours)

    Blood samples will be collected to determine the AUC0-24 of rosuvastatin.

  6. Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Furosemide

    Time frame: At designated time points (up to approximately 24 hours)

    Blood samples will be collected to determine the AUC0-24 of furosemide.

  7. Maximum Plasma Concentration (Cmax) of Rosuvastatin

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the Cmax of rosuvastatin.

  8. Maximum Plasma Concentration (Cmax) of Furosemide

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the Cmax of furosemide.

  9. Time of the Maximum Plasma Concentration (Tmax) of Rosuvastatin

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the Tmax of rosuvastatin.

  10. Time of the Maximum Plasma Concentration (Tmax) of Furosemide

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the Tmax of furosemide.

  11. Terminal Half-life (t1/2) of Rosuvastatin

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the t1/2 of rosuvastatin.

  12. Terminal Half-life (t1/2) of Furosemide

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the t1/2 of furosemide.

  13. Apparent Total Plasma Clearance (CL/F) of Rosuvastatin

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the CL/F of rosuvastatin.

  14. Apparent Total Plasma Clearance (CL/F) of Furosemide

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the CL/F of furosemide.

  15. Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Rosuvastatin

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the Vz/F of rosuvastatin.

  16. Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Furosemide

    Time frame: At designated time points (up to approximately 2 weeks)

    Blood samples will be collected to determine the Vz/F of furosemide.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 25, 2026
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.